Amit

Analyst

H.C. Wainwright

Equibles does not estimate personal net worth.

About Amit

Amit is recorded as Analyst at H.C. Wainwright. Amit has spoken on 2 earnings calls across 2 companies, most recently for Halozyme Therapeutics, Inc. on November 5, 2026. Those appearances were for Halozyme Therapeutics, Inc. (HALO) and Incyte Corp (INCY). The companies whose calls Amit spoke on are classified in the Healthcare sector.

Amit on recent calls

“So for subcutaneous ablentamab, is the Phase 1B study designed primarily to establish peak comparability, or are you also looking at peak exposure and how that improves safety?”

Analyst — H.C. Wainwright, Halozyme to Report Third Quarter 2026 Financial and Operating Results · November 5, 2026

“I guess looking at 734 and DON302, what supports 734 and cetoximab combo replacing second-line chemo? And will the 302 second-line cohort be large enough to establish benefit independently of third-line results?”

Analyst — H.C. Wainwright, Q3 2026 Incyte Corporation Earnings Conference Call · October 29, 2026